Market cap
$1.2bn
Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.
Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.
We anticipate that we will require significant additional financing in the future to continue to fund our operations as discussed more fully below under the heading “Liquidity and Capital Resources.” Financial Operations Overview Product Revenue, Net Our first commercial product, KOMZIFTI, was approved by the FDA for sale in the United States on November 13, 2025. Revenue from Collaborations and Licenses We generate revenue primarily through collaboration and license agreements, such as the Kyowa License Agreement. …Kura Oncology, Inc., 10-K, period ended 2025-12-31, filed 2026-03-05